Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Dosing Schedule Modification of COVID-19 Vaccine in Immunosuppressed and Cancer Patient: A Review of Current Suggestions

Version 1 : Received: 29 January 2023 / Approved: 31 January 2023 / Online: 31 January 2023 (06:26:20 CET)

How to cite: Rahman, M. T.; Rahman, H.; Shad, A. Dosing Schedule Modification of COVID-19 Vaccine in Immunosuppressed and Cancer Patient: A Review of Current Suggestions. Preprints 2023, 2023010576. https://doi.org/10.20944/preprints202301.0576.v1 Rahman, M. T.; Rahman, H.; Shad, A. Dosing Schedule Modification of COVID-19 Vaccine in Immunosuppressed and Cancer Patient: A Review of Current Suggestions. Preprints 2023, 2023010576. https://doi.org/10.20944/preprints202301.0576.v1

Abstract

The effect of SARS-CoV-2 pandemic has been subsided significantly following the rapid development of vaccine. However, patients with cancer and immunosuppressed state, who are more prone to mortality and morbidity due to this infection, were excluded from majority of the vaccine trials. Moreover, suggested dose modification for cancer and immunosuppressed patients are often not followed because of lack of awareness or unavailability of vaccination schedule. This review will try to bridge this knowledge gap by summarizing the current suggestions of dose modification of COVID-19 vaccine for patients with cancer and immunosuppression.

Keywords

COVID-19; vaccine; immunosuppressed; cancer; vaccine efficacy

Subject

Medicine and Pharmacology, Medicine and Pharmacology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.